KD Logo

An Analysis of SpringWorks Therapeutics Inc (SWTX)’s Potential Price Growth

SpringWorks Therapeutics Inc’s recently made public that its Chief People Officer Pichl Daniel unloaded Company’s shares for reported $0.75 million on Feb 16 ’24. In the deal valued at $50.10 per share,15,000 shares were sold. As a result of this transaction, Pichl Daniel now holds 45,212 shares worth roughly $2.11 million.

Then, Ashar Bhavesh sold 4,834 shares, generating $238,435 in total proceeds. Upon selling the shares at $49.32, the Chief Commercial Officer now owns 58,154 shares.

Before that, Pichl Daniel sold 26,181 shares. SpringWorks Therapeutics Inc shares valued at $1,160,362 were divested by the Chief People Officer at a price of $44.32 per share. As a result of the transaction, Pichl Daniel now holds 45,212 shares, worth roughly $2.11 million.

Guggenheim initiated its SpringWorks Therapeutics Inc [SWTX] rating to a Buy in a research note published on February 05, 2024; the price target was $75. A number of analysts have revised their coverage, including BofA Securities’s analysts, who began to cover the stock in early December with a ‘”a Buy”‘ rating. H.C. Wainwright also remained covering SWTX and reiterated its “Buy” recommendation on January 19, 2021. H.C. Wainwright maintained its rating on October 29, 2020. It rated SWTX as “a Buy”.

Price Performance Review of SWTX

On Tuesday, SpringWorks Therapeutics Inc [NASDAQ:SWTX] saw its stock jump 0.52% to $46.69. Over the last five days, the stock has gained 6.11%. SpringWorks Therapeutics Inc shares have risen nearly 27.92% since the year began. Nevertheless, the stocks have risen 99.70% over the past one year. While a 52-week high of $53.92 was reached on 03/08/24, a 52-week low of $18.00 was recorded on 01/02/24. SMA at 50 days reached $47.44, while 200 days put it at $34.58. A total of 1.1 million shares were traded, compared to the trading of 0.8 million shares in the previous session.

Levels Of Support And Resistance For SWTX Stock

The 24-hour chart illustrates a support level at 45.43, which if violated will result in even more drops to 44.17. On the upside, there is a resistance level at 47.99. A further resistance level may holdings at 49.28. The Relative Strength Index (RSI) on the 14-day chart is 55.38, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 2.47, which suggests price will go up in the next trading period. Percent R suggests that price movement has been bullish at 14.58%. Stochastics %K at 87.96% indicates the stock is a selling.

The most recent change occurred on May 05, 2020 when Barclays began covering the stock and recommended ‘”an Overweight”‘ rating along with a $48 price target.

Most Popular

[the_ad id="945"]